Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Another insightful post by Paulsnowmam!

"SRNE. AMGEN. ENBREL & 2 SUPER BLOCKBUSTERS (SP102 / ABIVERTINIB)

Great article from BIOPHARMA DIVE about AMGEN, and Its super blockbuster drug Enbrel. Enbrel and Sorrento’s device Sofusa DoseConnect are currently part of a clinical trial.

clinicaltrials.gov/ct2/show...

Drugmakers often gauge the potential of their products by whether annual sales can eclipse $1 billion. Large pharmaceutical companies have a handful of these “blockbusters,” while successful biotechs might have one or two. SORRENTO a biotech under 2B MC has two potential super blockbusters (over 10B) in SP102 and Abivertinib (NSCLC) which should be approved in 2022. When including Abivertinib as a super blockbuster, I included it’s indications in which we should see approval or EUA (NSCLC / 5656.

https://www.biopharmadive.com/news/amgen-enbrel-patent-thicket-monopoly-biosimilar/609042/

There are many reasons to invest in SRNE. There’s been a lack of focus and mismanagement by the company, and long term manipulation by outside parties, but for those investors that do their research there are many obvious reasons this is not your normal small biotech company. For those inpatient investors remember that in 2022, and not 3-5 years down the line, there will be not one but two approvals, and a likely EUA.

We should get more SP102 data in January, and hopefully ACEA Abivertinib China approval as well. Both of these are significant, and will move the SP. Happy New Year."